Cargando…
Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study
BACKGROUND: Although several new drugs have been approved in recent years, pulmonary arterial hypertension (PAH) remains a rapidly progressive disease with a poor prognosis. Ambrisentan, a selective endothelin type A antagonist, has been approved for treatment of PAH. This open label study assessed...
Autores principales: | Huo, Y., Jing, Z. C., Zeng, X. F., Liu, J. M., Yu, Z. X., Zhang, G. C., Li, Y., Wang, Y., Ji, Q. S., Zhu, P., Wu, B. X., Zheng, Y., Wang, P. P., Li, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075402/ https://www.ncbi.nlm.nih.gov/pubmed/27770771 http://dx.doi.org/10.1186/s12872-016-0361-9 |
Ejemplares similares
-
Open label study of ambrisentan in patients with exercise pulmonary hypertension
por: Segrera, Sergio A., et al.
Publicado: (2017) -
Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis
por: Li, Mengtao, et al.
Publicado: (2020) -
Ambrisentan for the treatment of pulmonary arterial hypertension
por: Casserly, Brian, et al.
Publicado: (2009) -
P1417: PROPHYLACTIC NAC PROMOTED HEMATOPOIETIC RECONSTITUTION BY IMPROVING ENDOTHELIAL CELLS AFTER HSCT: A PHASE 3, OPEN-LABEL RANDOMIZED TRIAL
por: Wang, Y., et al.
Publicado: (2022) -
A multi-center, controlled, randomized, open-label clinical study of levofloxacin for preventing infection during the perioperative period of ultrasound-guided transrectal prostate biopsy
por: Qiao, L.-D., et al.
Publicado: (2016)